Dec 25, 2019
Molecule is an open market based platform that incentivizes the development and co-creation of pharmaceutical IP. Molecule’s CEO, Devon Krantz, discusses the dire state of pharmacological R&D and its cost—literally and figuratively—to patients. Molecule, on the other hand, encourages a patient-centric approach to pharma. How? Devon puts it this way: “We are focusing more on bio-techs, on smaller research labs, on academia. [What we] want to incentivize is for researchers, scientists, and academics to take their IP, and maybe it's in an underfunded area, and put it onto the Blockchain, into an open market, which then enables other people to buy into the market and freely grow that market. We’re democratizing access to cures.” Devon elaborates on the innovative and complex ‘why & how’ during the rest of the conversation.